Patents by Inventor Sebastian Bernales

Sebastian Bernales has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY
    Publication number: 20200270232
    Abstract: The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway.
    Type: Application
    Filed: February 24, 2020
    Publication date: August 27, 2020
    Inventors: Sebastian BERNALES, Luz Marina DELGADO OYARZO, Gonzalo Esteban NÙÑEZ VASQUEZ, Gonzalo Andrés URETA DÍAZ, Brahmam PUJALA, Dayanand PANPATIL
  • INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN
    Publication number: 20200216417
    Abstract: Compounds and compositions for modulating fibroblast activation protein (FAP) are described. The compounds and compositions may find use as therapeutic agents for the treatment of diseases, including hyperproliferative diseases.
    Type: Application
    Filed: January 3, 2020
    Publication date: July 9, 2020
    Inventors: Sebastian BERNALES, Brahmam PUJALA, Dayanand PANPATIL, Gonzalo Andrés URETA DÍAZ, Sebastian BELMAR
  • INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN
    Publication number: 20200206216
    Abstract: Compounds and compositions for modulating fibroblast activation protein (FAP) are described. The compounds and compositions may find use as therapeutic agents for the treatment of diseases, including hyperproliferative diseases.
    Type: Application
    Filed: December 21, 2019
    Publication date: July 2, 2020
    Inventors: Brahmam Pujala, Dayanand Panpatil, Sebastian Bernales, Sebastian Belmar, Gonzalo Andrés Ureta Díaz
  • INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY
    Publication number: 20200101047
    Abstract: The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway.
    Type: Application
    Filed: June 5, 2019
    Publication date: April 2, 2020
    Inventors: Luz Marina DELGADO OYARZO, Gonzalo Andrés URETA DÍAZ, Brahmam PUJALA, Dayanand PANPATIL, Sebastian BERNALES, Sarvajit CHAKRAVARTY
  • ATF6 INHIBITORS AND USES THEREOF
    Publication number: 20190367497
    Abstract: Compounds as inhibitors of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatment of viral infections, neurodegenerative diseases, vascular diseases, or cancer.
    Type: Application
    Filed: April 6, 2019
    Publication date: December 5, 2019
    Inventors: Jennifer ALFARO, Sebastian BELMAR, Gonzalo Esteban NÚÑEZ VASQUEZ, Brahmam PUJALA, Balaji Dashrath SATHE, Pooja THAKRAL, Rajesh Kumar PATIDAR, Sebastian BERNALES, Sarvajit CHAKRAVARTY
  • INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN
    Publication number: 20190185451
    Abstract: Compounds and compositions for modulating fibroblast activation protein (FAP) are described. The compounds and compositions may find use as therapeutic agents for the treatment of diseases, including hyperproliferative diseases.
    Type: Application
    Filed: December 14, 2018
    Publication date: June 20, 2019
    Inventors: Jennifer ALFARO, Sebastian BELMAR, Sebastian BERNALES, Brahmam PUJALA, Dayanand PANPATIL, Bhawana BHATT
  • INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY
    Publication number: 20190177310
    Abstract: The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway.
    Type: Application
    Filed: December 13, 2018
    Publication date: June 13, 2019
    Inventors: Sebastian BERNALES, Luz Marina DELGADO OYARZO, Gonzalo Esteban NÚÑEZ VASQUEZ, Gonzalo Andrés URETA DÍAZ, Brahmam PUJALA, Dayanand PANPATIL, Bhawana BHATT, Sarvajit CHAKRAVARTY
  • Heterocyclic compounds and methods of use
    Patent number: 10189826
    Abstract: This disclosure provides compounds and methods of using those compounds to treat metabolic disorders and hyperproliferative disorders, including administration of the compounds in conjunction with hormone receptor antagonists.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: January 29, 2019
    Assignee: Medivation Technologies LLC
    Inventors: Brahmam Pujala, Ramniwas Jangir, Rambabu Guguloth, Bharat Uttam Shinde, Roopa Rai, Son Minh Pham, Sebastian Bernales, Jeffrey Lindquist, Mausumee Guha, Satyanarayana Kallem, Bhawana Bhatt, Vikas Ramdas Bhagwat
  • Heterocyclic compounds and methods of use
    Patent number: 10183015
    Abstract: This disclosure provides compounds and methods of using those compounds to treat liver fibrosis, including liver fibrosis which is a precursor to, is concurrent with, is associated with, or is secondary to nonalcoholic steatohepatitis (NASH); elevated cholesterol levels, and insulin resistance.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: January 22, 2019
    Assignee: Medivation Technologies LLC
    Inventors: Sebastian Bernales, Jeffrey Lindquist, Mausumee Guha
  • Heterocyclic Compounds and Methods of Use
    Publication number: 20180051013
    Abstract: This disclosure provides compounds and methods of using those compounds to treat metabolic disorders and hyperproliferative disorders, including administration of the compounds in conjunction with hormone receptor antagonists.
    Type: Application
    Filed: March 4, 2016
    Publication date: February 22, 2018
    Inventors: Brahmam Pujala, Ramniwas Jangir, Rambabu Guguloth, Bharat Uttam Shinde, Roopa Rai, Son Minh Pham, Sebastian Bernales, Jeffrey Lindquist, Mausumee Guha, Satyanarayana Kallem, Bhawana Bhatt, Vikas Ramdas Bhagwat
  • Heterocyclic Compounds and Methods of Use
    Publication number: 20180028518
    Abstract: This disclosure provides compounds and methods of using those compounds to treat liver fibrosis, including liver fibrosis which is a precursor to, is concurrent with, is associated with, or is secondary to nonalcoholic steatohepatitis (NASH); elevated cholesterol levels, and insulin resistance.
    Type: Application
    Filed: March 3, 2016
    Publication date: February 1, 2018
    Inventors: Sebastian Bernales, Jeffrey Lindquist, Mausumee Guha
  • Targeted Therapeutics
    Publication number: 20170119907
    Abstract: This disclosure describes compositions and methods for delivering and localizing therapeutic agents to therapeutic targets. This disclosure also provides multivalent forms of cationic dyes (“cationic dye multimers”) and methods by which these compounds can be used to treat joint injuries.
    Type: Application
    Filed: January 28, 2015
    Publication date: May 4, 2017
    Applicant: Medivation Technologies, Inc.
    Inventors: David Hung, Sarvajit Chakravarty, Roopa Rai, Sebastian Bernales, Balaji Dashrath Sathe, Gonzalo Ureta, Emma McCullagh
  • Methods and compositions for modulating Ire1, SRC and ABL activity
    Patent number: 9382230
    Abstract: Disclosed herein are, inter alia, compositions for modulating Ire1, Src, or Abl, methods for identifying modulating activity in test compounds, and methods for treating diseases caused by the activity or inactivity of Ire1, Src, or Abl.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: July 5, 2016
    Assignee: The Regents of the University of California
    Inventors: Peter Walter, Alexei Korennykh, Kevan M. Shokat, Chao Zhang, Janet Finer-Moore, Robert Stroud, Pascal Egea, Andrei Korostelev, Arvin Dar, Sebastian Bernales
  • METHODS AND COMPOSITIONS FOR MODULATING IRE1, SRC, AND ABL ACTIVITY
    Publication number: 20150011575
    Abstract: Disclosed herein are, inter alia, compositions for modulating Ire1, Src, or Abl, methods for identifying modulating activity in test compounds, and methods for treating diseases caused by the activity or inactivity of Ire1, Src, or Abl.
    Type: Application
    Filed: July 2, 2014
    Publication date: January 8, 2015
    Inventors: Peter Walter, Alexei Korennykh, Kevan M. Shokat, Chao Zhang, Janet Finer-Moore, Robert Stroud, Pascal Egea, Andrei Korostelev, Arvin Dar, Sebastian Bernales
  • Methods and compositions for modulating IRE1, SRC, and ABL activity
    Patent number: 8815885
    Abstract: Disclosed herein are, inter alia, compositions for modulating Ire1, Src, or Abl, methods for identifying modulating activity in test compounds, and methods for treating diseases caused by the activity or inactivity of Ire1, Src, or Abl.
    Type: Grant
    Filed: September 15, 2009
    Date of Patent: August 26, 2014
    Assignee: The Regents of the University of California
    Inventors: Peter Walter, Alexei Korennykh, Kevan M. Shokat, Chao Zhang, Janet Finer-Moore, Robert Stroud, Pascal Egea, Andrei Korostelev, Arvin Dar, Sebastian Bernales
  • Methods and Compositions for Modulating IRE1, SRC, and ABL Activity
    Publication number: 20110319436
    Abstract: Disclosed herein are, inter alia, compositions for modulating Ire1, Src, or Abl, methods for identifying modulating activity in test compounds, and methods for treating diseases caused by the activity or inactivity of Ire1, Src, or Abl.
    Type: Application
    Filed: September 15, 2009
    Publication date: December 29, 2011
    Applicant: The Regents of the University of California
    Inventors: Peter Walter, Alexei Korennykh, Kevan M. Shokat, Chao Zhang, Janet Finer-Moore, Robert Stroud, Pascal Egea, Andrei Korostelev, Arvin Dar, Sebastian Bernales